TKI 963

Known as: TKI963 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2003-2018
0120032018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Multiple randomized clinical trials have demonstrated that epidermal growth factor receptor (EGFR) exon 19 deletion (19Del) and… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?
2017
2017
Objective To evaluate the progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell… (More)
Is this relevant?
2017
2017
STOP second generation (2G)-tyrosine kinase inhibitor (TKI) is a multicenter observational study designed to evaluate 2G-TKI… (More)
  • table 1
  • table 2
Is this relevant?
2016
2016
F Das 10 Jahres-Überleben für Patienten mit Chronisch Myeloischer Leukämie (CML) beträgt heute 83 Prozent. Patienten, die in… (More)
Is this relevant?
2015
2015
Purpose: VEGFR2 tyrosine kinase inhibition (TKI) is a valuable treatment approach for patients with metastatic renal cell… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
Das medulläre Schilddrüsenkarzinom (MTC) ist ein langsam wachsender differenzierter neuroendokriner Tumor mit guter Prognose und… (More)
Is this relevant?
2013
2013
We retrospectively analyzed metastatic renal cell carcinoma (RCC) patients treated with 3 targeted agents. Patients started the… (More)
Is this relevant?
Review
2012
Review
2012
With seven targeted agents, directed against the VEGF/VEGF receptor (VEGFR) axis or the mTOR pathway, approved for the treatment… (More)
  • table 1
  • table 2
  • figure 1
Is this relevant?
2003
2003
Activities of vascular smooth muscle cells (SMCs) such as proliferation, migration, and matrix production contribute to… (More)
Is this relevant?